Acepodia, Inc.

Acepodia is emerging as one of the world’s few developers of antibody-drug conjugates (ADCs) preparing to advance into the clinic with a dual payload-fixed design of targeted cancer therapy. Based out

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A

The volume of $100m-plus venture capital mega-rounds continues to build throughout 2023 after a slow start, but a wider look at the biopharmaceutical VC landscape illustrates the valley of death that

[Sidebar#SC145549] Biopharmaceutical companies and other life science start-ups may access $1.28bn in new venture capital available through four different sources, including Eir Venture Partners AB’s